CN106999499A - 一种氧代哌嗪酰胺类化合物的用途 - Google Patents

一种氧代哌嗪酰胺类化合物的用途 Download PDF

Info

Publication number
CN106999499A
CN106999499A CN201480082678.7A CN201480082678A CN106999499A CN 106999499 A CN106999499 A CN 106999499A CN 201480082678 A CN201480082678 A CN 201480082678A CN 106999499 A CN106999499 A CN 106999499A
Authority
CN
China
Prior art keywords
compound
formula
use according
sulbactam
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480082678.7A
Other languages
English (en)
Inventor
孙明杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangbei Wellman Pharmaceutical Co ltd
Original Assignee
Xiangbei Wellman Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangbei Wellman Pharmaceutical Co ltd filed Critical Xiangbei Wellman Pharmaceutical Co ltd
Publication of CN106999499A publication Critical patent/CN106999499A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02—Preparation
    • C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/32—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201480082678.7A 2014-10-28 2014-10-28 一种氧代哌嗪酰胺类化合物的用途 Pending CN106999499A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/089631 WO2016065525A1 (zh) 2014-10-28 2014-10-28 一种氧代哌嗪酰胺类化合物的用途

Publications (1)

Publication Number Publication Date
CN106999499A true CN106999499A (zh) 2017-08-01

Family

ID=55856347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480082678.7A Pending CN106999499A (zh) 2014-10-28 2014-10-28 一种氧代哌嗪酰胺类化合物的用途

Country Status (2)

Country Link
CN (1) CN106999499A (zh)
WO (1) WO2016065525A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882360A (zh) * 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5325589A (en) * 1976-08-03 1978-03-09 Toyama Chem Co Ltd Novel process for preparation of penicillins and cephalosporins
JPS6041681A (ja) * 1984-05-02 1985-03-05 Toyama Chem Co Ltd セフアロスポリンの新規製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882360A (zh) * 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations

Also Published As

Publication number Publication date
WO2016065525A1 (zh) 2016-05-06

Similar Documents

Publication Publication Date Title
JP6533780B2 (ja) 細菌性感染症の治療に用いるためのオキサゾリジノン−キノロン類を含む組み合わせ療法
EP2793892A1 (en) Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of pi3k/mtor with bendamustine and/or rituximab
KR20090023585A (ko) Ｇｓｋ-3 억제제로서의 ｎ-(2-티아졸릴)-아미드 유도체
RU2671485C2 (ru) Антибиотические композиции тазобактама аргинина
TW201336497A (zh) 噻唑啶二酮化合物之結晶型及其製法
US10849886B2 (en) Combination therapy using azabicyclo compound for cancer
JP2020508340A (ja) 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
BR112020016929A2 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
WO2019228524A1 (zh) 用于治疗肾癌的药物组合物及其应用
WO2014183673A1 (zh) 阿那格雷及其衍生物的抗肿瘤用途
CN109999027B (zh) 褪黑素的用途
AU2004220205B2 (en) Antitumor effect potentiator and antitumor agent
JP6264685B2 (ja) マルチキナーゼ阻害剤、抗癌剤、抗転移剤、薬剤耐性抑制剤、疼痛抑制剤及び止痒薬
CN102626408B (zh) 吲哚满二酮缩氨基硫脲类化合物在制备抑制ndm-1活性的药物中的应用
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
CN106999499A (zh) 一种氧代哌嗪酰胺类化合物的用途
WO2016083992A1 (en) Titled extracts of cynara scolymus and uses thereof
CN105616414B (zh) 一种氧代哌嗪酰胺类化合物的新用途
CN115518056A (zh) 橙花叔醇、橙花醇和香叶醇在抗菌方面的用途
CN101418015B (zh) 头孢曲松磷酰化衍生物
CN108619145B (zh) 化合物在治疗肿瘤中的应用
JP2021504452A (ja) ジシクロプラチンを含有する組み合わせ製剤、その調製及びその使用
JP2767176B2 (ja) 抗癌剤
CA2497410A1 (en) Antibacterial pyrazole carboxylic acid hydrazides
CN115040519A (zh) Egfr抑制剂用于治疗非常见或非经典突变的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801